Catheter Precision secures up to $36.5M institutional financing; converts $9M liabilities into equity

Catheter Precision, Inc.

CEO David Jenkins exchanged royalty rights for ~9,490 shares of Series J Preferred Stock convertible into 6,083,005 common shares at $1.56, subject to stockholder approval.
ATM equity offering program terminated; no future equity lines or forward-priced agreements anticipated.
Short-term notes converted to long-term debt with maturities of 2-3 years.
Additional $9M in short and long-term liabilities converted into equity, strengthening balance sheet.
Up to $36.5M in institutional financing secured to expand market presence and advance growth initiatives.

item 1.01 item 3.02 item 5.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Catheter Precision, Inc. issued 9,489.488 shares of Series J Preferred Stock of preferred stock to David A. Jenkins and FatBoy Capital, LP for accrued royalty amounts totaling a net present value equal to $9,489,487.81.

Security: preferred stock
Shares: 9,489.488 shares of Series J Preferred Stock
Purchaser: David A. Jenkins and FatBoy Capital, LP
Consideration: accrued royalty amounts totaling a net present value equal to $9,489,487.81

Exact text from the filing

Settlement Agreements dated January 9, 2023 between the Company and the Holders previously disclosed by the Company accrued royalty amounts totaling a net present value equal to $9,489,487.81 as of December 31, 2025 are being exchanged for 9,489.488 shares of Series J Preferred Stock, collectively. Per the Exchange Agreements, the accrued royalty amounts and the

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

Catheter Precision, Inc.: Filed Series J Certificate of Designation with Delaware Secretary of State on February 9, 2026, as corrected on February 12, 2026, to establish Series J Convertible Preferred Stock (effective 2026-02-09).

Change: charter amendment
Effective: 2026-02-09

Exact text from the filing

as further described by the Certificate of Designation of Preferences, Rights and Limitations of Series J Convertible Preferred Stock which was filed with the Delaware Secretary of State on February 9, 2026, as corrected on February 12, 2026 (the "Series J Certificate of Designation")

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Catheter Precision, Inc. entered into Series J Exchange Agreements with David A. Jenkins and FatBoy Capital, LP valued at $9,489,487.81 (effective 2026-02-12).

Action: entry
Agreement: equity purchase
Counterparty: David A. Jenkins and FatBoy Capital, LP
Value: $9,489,487.81
Effective: 2026-02-12

Exact text from the filing

On February 12, 2026, Catheter Precision, Inc., a Delaware corporation (the "Company"), entered into Series J Exchange Agreements (the "Exchange Agreements") with David A. Jenkins and FatBoy Capital, LP. (the "Holders") to convert royalty rights and accrued royalty right amounts into 2,491.293 shares and 6,998.195 shares, respectively of the Company's newly created Series J Convertible Preferred Stock

View on SEC.gov

25 equity issuances filed in the last 30 days. Browse all equity issuances →

Catheter Precision, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-003940

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.